To increase the tumor-specific delivery of TOP1 inhibitors, and hence their accumulation in cancers, TOP1-ADCs and nanoparticulate formulations have been developed; the latter include liposomes, polymeric nanoparticles, and functionalized carbon nanotubes [26,27,28,29,30]. The gene discussed is TOP1; the disease is cancer.